Next, we evaluated the correlation between total EGFR expression and insensitivity to lorlatinib in seven ALK-rearranged NSCLC cell lines to subsequently assess the additional efficacy of erlotinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.